April 2th
2008
6:44 PM
A British study suggests that Singulair should be studied for possible psychiatric adverse drugs reactions in children. I don't have this access to this journal so I have to try to find it. I will get back to you on what it says specifically.
BMC Clin Pharmacol. 2008 Mar 17;8(1):1 Links
Individual case safety reports in children in commonly used drug groups - signal detection.Brunlof G, Tukukino C, Wallerstedt SM.
ABSTRACT: BACKGROUND: Due to few paediatric drug safety studies, knowledge on risks of drug treatment in children is limited. The knowledge needs to be increased to make proper risk-benefit analyses possible when treating paediatric patients with drugs. The aim of the present study was to investigate drug groups commonly used in children concerning type and frequency of individual case safety reports in children. METHODS: Number and type of individual case safety reports in the 30 groups of drugs (5th level ATC-code) most sold (number of defined daily doses) in outpatient treatment to children (<5 years old and experiencing psychiatric adverse drug reactions. CONCLUSION: The number of individual case safety reports per million defined daily doses varies in different groups of drugs. A possible signal for montelukast and psychiatric adverse drug reactions was found, which should be further explored.
PMID: 18366638
The key sentence is:
A POSSIBLE SIGNAL FOR MONTELUKAST (SINGULAIR) AND PSYCHIATRIC ADVERSE DRUG REACTIONS WAS FOUND, WHICH SHOULD BE FURTHER EXPLORED.
-- By concernedcitizen | Reply | (2) replies | Private Message me
March 31th
2008
11:16 AM
I am Cody Millers mom ,the boy who died from Suicide while on Singulair for 17 days, I just wanted to say one thing to all of you that take the time to post.GO ONE STEP FURTHER CONTACT THE FDA and report to medwatch .The investigation needs evidence like your stories to help make informed decisions about this drug.The poorly orchestrated disclosing campaign that Merck had supposedly set out to accomplish in 2007, has obviously not reached the mass majority of people using this drug .Seeing now how many people did not make the connection to these HIDDEN AND DANGEROUS SIDE EFFECTS.Our child's pharmacy sheet that came with the medicine ,showed none of the updated side effects.They were added in April 2007,I filled the prescription in July 2007.Nothing had been disclosed until we put forth this effort to get the FDA's attention ,by asking the Senate and Congress to look into this matter.Go to your doctor and insist that they report YOUR SIDE EFFECTS to the company and the FDA.It is of the utmost importance.,Kate and Dave M.
-- By kate2 | Reply | (8) replies | Private Message me
April 2th
2008
10:03 PM
Artie commented below. I am posting Artie's comment back in a place where every one will see because I know the importance of arming yourself with research. I have worked for a major pharmaceutical company in my lifetime. I know that we need research and we need proof. Without that, we will be ignored.
Reply 1 minute ago on Apr 02, 2008 by artie81, #6536
-- By concernedcitizen | Reply | (1) replies | Private Message meDo you honestly think the people on this forum know how to interpret scholarly journal artcles?
Posted at 6:44 PM on Apr 02, 2008 by concernedcitizen, #29028
A British study suggests that Singulair should be studied for possible psychiatric adverse drugs reactions in children. I don't have this access to this journal so I have to try to find it. I will get back to you on what it says specifically. BMC Clin Pharmacol. 2008 Mar 17;8(1):1 Links Individual case safety reports in children in commonly used drug groups - signal detection.Brunlof G, Tukukino C, Wallerstedt SM. ABSTRACT: BACKGROUND: Due to few paediatric drug safety studies, knowledge on risks of drug treatment in children is limited. The knowledge needs to be increased to make proper risk-benefit analyses possible when treating paediatric patients with drugs. The aim of the present study was to investigate drug groups commonly used in children concerning type and frequency of individual case safety reports in children. METHODS: Number and type of individual case safety reports in the 30 groups of drugs (5th level ATC-code) most sold (number of defined daily doses) in outpatient treatment to children (<5 years old and experiencing psychiatric adverse drug reactions. CONCLUSION: The number of individual case safety reports per million defined daily doses varies in different groups of drugs. A possible signal for montelukast and psychiatric adverse drug reactions was found, which should be further explored. PMID: 18366638 The key sentence is: A POSSIBLE SIGNAL FOR MONTELUKAST (SINGULAIR) AND PSYCHIATRIC ADVERSE DRUG REACTIONS WAS FOUND, WHICH SHOULD BE FURTHER EXPLORED.